GRAIL, Inc. (GRAL)
| Market Cap | 6.28B +177.3% |
| Revenue (ttm) | 165.26M +23.1% |
| Net Income | -391.59M |
| EPS | -9.75 |
| Shares Out | 44.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 774,108 |
| Open | 133.50 |
| Previous Close | 132.61 |
| Day's Range | 133.31 - 142.57 |
| 52-Week Range | 41.50 - 166.48 |
| Beta | 2.84 |
| Analysts | Buy |
| Price Target | 116.10 (-17.41%) |
| Est. Earnings | Nov 11, 2026 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology... [Read more]
Financial Performance
In 2025, GRAIL's revenue was $147.17 million, an increase of 17.18% compared to the previous year's $125.60 million. Losses were -$408.35 million, -79.85% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for GRAL stock is "Buy." The 12-month stock price target is $116.1, which is a decrease of -17.41% from the latest price.
News
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to P...
Grail price target raised to $175 from $105 at UBS
UBS raised the firm’s price target on Grail (GRAL) to $175 from $105 and keeps a Buy rating on the shares. Following the FDA panel and Centers for Medicare and…
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
An advisory panel to the US Food and Drug Administration handed Grail's Galleri blood test a milestone win last week, saying the early cancer detection test's potential benefits outweigh its risks and...
Grail price target raised to $155 from $75 at Guggenheim
Guggenheim raised the firm’s price target on Grail (GRAL) to $155 from $75 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for select…
Grail price target raised to $150 from $80 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Grail (GRAL) to $150 from $80 and keeps a Buy rating on the shares. The firm increased Grail’s revenue estimates…
Grail price target raised to $100 from $65 at Mizuho
Mizuho raised the firm’s price target on Grail (GRAL) to $100 from $65 and keeps a Neutral rating on the shares. The FDA panel voted that Galleri is safe, effective,…
Grail panel votes ‘closer than we expected,’ says BTIG
BTIG analyst Mark Massaro says following the FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee for the Galleri cancer test from Grail (GRAL) that while the…
AdCom meeting for Grail’s Galleri test better than expected, says Canaccord
Canaccord keeps a Buy rating and an $80 price target on Grail (GRAL), noting the firm remains bullish on the shares as the AdCom meeting for the company’s Galleri test…
TD ups Grail approval probability to 95% after panel vote
TD Cowen analyst Dan Brennan views the end result of the FDA panel meeting as solid for Grail (GRAL). The panel voted 7-2 with in favor of Galleri’s benefit to…
Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.
Grail says FDA panel recommendations ‘reaffirm high evidence bar’ for Galleri
Grail (GRAL) announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee of the U.S. Food and Drug Administration for the approval…
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular an...
FDA panel votes in favor of Grail’s Galleri benefits outweighing risks
The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee voted to recommend approval for Grail’s (GRAL) Galleri, a blood test designed to screen for multiple types…
FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy
A panel of outside experts advising the US FDA backed the safety of Grail's blood-based cancer detection test, Galleri, on Wednesday, but was divided on the evidence supporting its effectiveness.
Grail wins FDA panel backing for blood test to detect cancer, Bloomberg says
17:48 EDT Grail (GRAL) wins FDA panel backing for blood test to detect cancer, Bloomberg says
FDA panel votes 6-4 that Grail’s Galleri test is effective, Bloomberg says
The FDA’s advisory committee has voted 10-0 to determine that Grail’s (GRAL) Galleri blood test to detect cancer is safe, Bloomberg reports. The committee also voted 6-4 that the test…
FDA panel says Grail’s cancer detection blood test is safe, Bloomberg says
17:26 EDT FDA panel says Grail’s (GRAL) cancer detection blood test is safe, Bloomberg says
Grail price target raised to $118 from $86 at Baird
Baird analyst Robert Bamberger raised the firm’s price target on Grail (GRAL) to $118 from $86 and keeps an Outperform rating on the shares after the FDA released Galleri AdComm…
Grail FDA briefing documents ‘amicable’ to approval, says Mizuho
Mizuho says Grail (GRAL) shares rallied on the the details of the briefing documents posted to the FDA website regarding the Galleri advisory committee meeting taking place on September 23.
Grail rallies as FDA staff flags no major concerns for multi-cancer test
The US FDA's staff reviewers did not raise major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers, sending the company's shares soaring 35% on Mond...
Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review From FDA
The biotech meets with the Food and Drug Administration this week for premarket approval of its landmark cancer blood test.
Grail rallies after FDA releases briefing documents for Galleri test review
Shares of Grail (GRAL) are up $24.76, or 31%, to $105.53 after the FDA posted briefing documents ahead of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory…